Barely Significant
← all excerpts

Future perspectives in diabesity treatment: Semaglutide, a glucagon-like peptide 1 receptor agonist (Review).

Exp Ther Med · 2021 · PMC8394024 · PMID 34504612

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantP<0.001actually significant
At week 68, the mean body weight change was highly significant in the semaglutide group vs. the placebo group (-14.9 vs. -2.4%; ETD, -12.4%; P<0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.